Radius Health (RDUS) Shares are Down -3.98%

Radius Health (RDUS) has risen sharply, recording gains of 15.22% in the past 4 weeks. However, the stock has corrected -3.98% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 15.46% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.

For the current week, the company shares have a recommendation consensus of Buy. The stock has recorded a twenty day Moving Average of 1.31% and the fifty day Moving Average is 20.17%. Radius Health, Inc. is up 54.89% in the last three month period. Year-to-Date the stock performance stands at -11.78%.

Radius Health (RDUS) : The highest level Radius Health (RDUS) is projected to reach is $70 for the short term and the lowest estimate is at $24. The consolidated price target from 5 rating analysts who initiate coverage on the stock is $52.2 and the possibility the share price can swing is $18.36.


Radius Health (NASDAQ:RDUS): stock turned positive on Friday. Though the stock opened at $53.3, the bulls momentum made the stock top out at $54.61 level for the day. The stock recorded a low of $52.52 and closed the trading day at $54.29, in the green by 1.80%. The total traded volume for the day was 1,006,724. The stock had closed at $53.33 in the previous days trading.

Radius Health, Inc. is a science-driven biopharmaceutical company focused on developing therapeutics for patients with osteoporosis, as well as other serious endocrine-mediated diseases. The Companys lead product candidate is abaloparatide (BA058), a bone anabolic for use in the reduction of fractures in postmenopausal osteoporosis delivered through subcutaneous injection, which it refers to as abaloparatide-SC and is in Phase III development. The Company is leveraging its investment in Abaloparatide-SC to develop a line extension that is designed to improve patient convenience by enabling administration of abaloparatide through an investigational short-wear-time patch, which the Company refers to as abaloparatide-TD. The Companys clinical product portfolio also includes the investigational drug RAD1901, a selective estrogen receptor down regulator/degrader (SERD) and RAD140, a nonsteroidal selective androgen receptor modulator (SARM), for the treatment of breast cancer.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.